WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a global clinical research organization in the design, development, and management of complex clinical trials and patient registries for many of the world's leading pharmaceutical and biotechnology companies, announced today that it has appointed Philip L. Calamia as its interim Chief Financial Officer, effective May 2, 2008. Encorium is continuing its search for a permanent CFO and hopes to provide an update in the coming weeks.
